DZ1877A1 - Forme posologiques d'azithromycine pour le traitement d'infection microbiennes. - Google Patents

Forme posologiques d'azithromycine pour le traitement d'infection microbiennes.

Info

Publication number
DZ1877A1
DZ1877A1 DZ950046A DZ950046A DZ1877A1 DZ 1877 A1 DZ1877 A1 DZ 1877A1 DZ 950046 A DZ950046 A DZ 950046A DZ 950046 A DZ950046 A DZ 950046A DZ 1877 A1 DZ1877 A1 DZ 1877A1
Authority
DZ
Algeria
Prior art keywords
azithromycin
treatment
dosage form
microbial infections
infections
Prior art date
Application number
DZ950046A
Other languages
English (en)
Inventor
William J Curatolo
George H Foulds
Hylar L Friedman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22883977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ1877(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DZ1877A1 publication Critical patent/DZ1877A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DZ950046A 1994-04-29 1995-04-26 Forme posologiques d'azithromycine pour le traitement d'infection microbiennes. DZ1877A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/235,069 US5605889A (en) 1994-04-29 1994-04-29 Method of administering azithromycin

Publications (1)

Publication Number Publication Date
DZ1877A1 true DZ1877A1 (fr) 2002-02-17

Family

ID=22883977

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ950046A DZ1877A1 (fr) 1994-04-29 1995-04-26 Forme posologiques d'azithromycine pour le traitement d'infection microbiennes.

Country Status (31)

Country Link
US (2) US5605889A (fr)
EP (1) EP0679400B1 (fr)
JP (3) JPH07300420A (fr)
KR (1) KR100354310B1 (fr)
CN (1) CN1088362C (fr)
AP (1) AP566A (fr)
AT (1) ATE183395T1 (fr)
AU (1) AU709328B2 (fr)
CA (1) CA2148071C (fr)
CO (1) CO4560547A1 (fr)
DE (1) DE69511451T2 (fr)
DK (1) DK0679400T3 (fr)
DZ (1) DZ1877A1 (fr)
ES (1) ES2136247T3 (fr)
FI (1) FI952060L (fr)
GR (1) GR3031290T3 (fr)
HU (1) HUT75244A (fr)
IL (1) IL113437A (fr)
LV (1) LV10918B (fr)
MA (1) MA23533A1 (fr)
NO (1) NO314386B1 (fr)
NZ (1) NZ548384A (fr)
OA (1) OA10151A (fr)
RU (1) RU2128998C1 (fr)
SI (1) SI0679400T1 (fr)
TN (1) TNSN95046A1 (fr)
TW (1) TW499311B (fr)
UA (1) UA34464C2 (fr)
UY (1) UY23935A1 (fr)
YU (1) YU49483B (fr)
ZA (1) ZA953439B (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0758244B2 (fr) † 1994-05-06 2008-02-13 Pfizer Inc. Formes galeniques a liberation controlee de l'azithromycine
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
MX9706062A (es) * 1995-02-08 1997-10-31 Yamanouchi Europ Bv FORMAS DE DOSIFICACION ORAL CONTENIENDO UN ANTIBIOTICO DE beta -LACTAMA.
US20060003447A1 (en) * 2003-12-30 2006-01-05 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US6383810B2 (en) * 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
US20030212123A1 (en) * 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
US6146655A (en) * 1997-08-29 2000-11-14 Softy-Flex Inc. Flexible intra-oral bandage and drug delivery system
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
US6861411B1 (en) 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
ATE234103T1 (de) * 1997-12-22 2003-03-15 Schering Corp Feste, oral verabreichbare ribavirin dosisformen und verfahren zu deren herstellung
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
ES2255490T3 (es) * 1999-03-31 2006-07-01 Janssen Pharmaceutica N.V. Almidon pregelatinizado en una formulacion de liberacion controlada.
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
ES2260047T3 (es) * 2000-07-25 2006-11-01 Laboratorio Silanes, S.A. De C.V. Proceso de etapa unica para la preparacion de 7,16-deoxi-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihidroxi-6-etil-3,5,9,11,13,15-hexametilbiciclo(11.2.1)hexadeca-1(2)-en-ona y obtencion de una forma nueva de 9-deoxo-9a-metil-9a-homoeritromicina a.
WO2002015842A2 (fr) 2000-08-23 2002-02-28 Wockhardt Limited Procede de preparation d'azithromycine anhydre
JP2004521615A (ja) * 2000-11-06 2004-07-22 インヴィトロジェン コーポレーション 乾燥粉末細胞および細胞培養試薬およびその生産の方法
US7119076B2 (en) * 2000-11-15 2006-10-10 Masao Sugamata Preventives or remedies for endometriosis or uterine myoma
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
EP1652851A1 (fr) 2001-05-22 2006-05-03 Pfizer Products Inc. Nouvelle forme cristalline de l'azithromycine
DK1390377T3 (da) * 2001-05-22 2006-06-19 Pfizer Prod Inc Ny krystalform af azithromycin
EP1418924A2 (fr) * 2001-08-21 2004-05-19 Pfizer Products Inc. Azithromycine unidose pour le traitement des infections respiratoires
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
AU2006218279B2 (en) * 2001-09-28 2009-12-10 Novartis Ag Pharmaceutical compositions comprising colloidal silicon dioxide
EP1541134A3 (fr) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Compositions stabilisées de azithromycin
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
EP1446010B1 (fr) * 2001-10-18 2009-04-15 Teva Pharmaceutical Industries Ltd. Compositions d'azithromycine stabilisees
AU2002353316A1 (en) * 2001-12-21 2003-07-09 Pfizer Products Inc. Methods for wet granulating azithromycin
PL371259A1 (pl) * 2001-12-21 2005-06-13 Pfizer Products Inc. Bezpośrednio sprasowywalne preparaty azytromycyny
CA2472588A1 (fr) * 2002-01-16 2003-07-31 Pepgen Corporation Administration par voie orale d'interferons-tau
BR0307331A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formulações granuladas a seco de azitromicina
RU2203670C1 (ru) * 2002-02-19 2003-05-10 Акционерное Курганское общество медицинских препаратов и изделий "Синтез" Лекарственный препарат антибактериального действия и способ его получения
WO2003074029A1 (fr) * 2002-03-07 2003-09-12 Vectura Limited Formulations a base de particules multiples a fusion rapide pour administration orale
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
BG748Y1 (bg) * 2002-07-02 2005-06-30 "BALKANFARMA-RAZGRAD" AD A{ô­{òM{}ö{ }{GC}{D A{DAAAAAAAAAAAAAAAAAAAAAAAAAA ЛЕКАРСТВЕНАБФОРМАБББББББББББББББББББББББББББББББББФЕДЙГБФЕХгЦдв@ЖЦЩФ@@@@@@@@@@@
RU2223103C1 (ru) * 2002-07-17 2004-02-10 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, обладающая антибактериальным действием
EP1594762A1 (fr) * 2003-02-19 2005-11-16 Teva Pharmaceutical Industries Limited Procede servant a stabiliser azithromycine pendant sa conservation par emballage dans un conteneur impermeable au gaz
RU2241985C1 (ru) * 2003-03-27 2004-12-10 Томский политехнический университет Способ количественного определения азитромицина дигидрата методом инверсионной вольтамперометрии
US8507000B2 (en) * 2003-05-06 2013-08-13 Nostrum Pharmaceuticals, Inc. Controlled release formulation of erythromycin derivatives
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
EP1648473B1 (fr) * 2003-07-24 2009-01-28 PLIVA HRVATSKA d.o.o. Dose unique a dissolution rapide d'azithromycine
TWI366442B (en) 2003-07-30 2012-06-21 Novartis Ag Palatable ductile chewable veterinary composition
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
WO2005053652A1 (fr) 2003-12-04 2005-06-16 Pfizer Products Inc. Compositions medicamenteuses cristallines multiparticulaires contenant un poloxamere et un glyceride
CN1697648B (zh) * 2003-12-04 2010-06-23 辉瑞产品公司 减少了副作用的阿奇霉素剂型
ATE399536T1 (de) * 2003-12-04 2008-07-15 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
CA2549225A1 (fr) * 2003-12-04 2005-06-16 Pfizer Products Inc. Procede d'atomisation/congelation faisant appel a une extrudeuse pour la preparation de compositions medicamenteuses cristallines multiparticulaires contenant de preference un poloxamere et un glyceride
EP1694304A2 (fr) * 2003-12-04 2006-08-30 Pfizer Products Inc. Formes de dosage multiparticulaire d'azythromycine obtenue par des procedes a base de liquide
BRPI0416534A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
WO2005053639A2 (fr) * 2003-12-04 2005-06-16 Pfizer Products Inc. Formes multiparticulaires a liberation controlee produites avec des optimiseurs de dissolution
CN1889931A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾－冻凝方法
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
JP2007517055A (ja) * 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答の増強
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
JP4713104B2 (ja) * 2004-08-04 2011-06-29 ファイザー株式会社 アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US20060182806A1 (en) * 2004-11-08 2006-08-17 Mintong Guo Extended-release propranolol composition
EA014249B1 (ru) * 2005-01-27 2010-10-29 Алембик Лимитед Формуляция леветирацетама длительного высвобождения
US20060198895A1 (en) * 2005-03-07 2006-09-07 Kotliar Eleonora M Azithromycin powder for oral suspension compositions
ES2328376T3 (es) * 2005-03-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Polvo de azitromicina para composiciones de suspension oral.
CN102048734B (zh) 2005-05-26 2013-11-20 大日本住友制药株式会社 药物组合物
WO2007018192A1 (fr) * 2005-08-10 2007-02-15 Shionogi & Co., Ltd. Comprimé pouvant être désintégré par voie orale
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
US8187659B2 (en) 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
GB0618966D0 (en) * 2006-09-26 2006-11-08 Iti Scotland Ltd Cartridge system
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2011122524A1 (fr) 2010-03-29 2011-10-06 アステラス製薬株式会社 Composition pharmaceutique à libération contrôlée
WO2013088274A1 (fr) 2011-12-14 2013-06-20 Wockhardt Limited Composition d'azithromycine amorphe anhydre dépourvue de dihydrate d'azithromycine
EP3216448B8 (fr) 2012-02-06 2019-06-05 Boehringer Ingelheim Animal Health USA Inc. Compositions vétérinaires orales parasiticides comprenant des agents actifs à action systémique, procédés et leurs utilisations
CN104168895B (zh) 2012-02-28 2020-02-21 首尔制药株式会社 包含西地那非作为活性成分的掩蔽苦味的高含量快速溶解膜
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
CN104177457A (zh) * 2013-05-23 2014-12-03 长春海悦药业有限公司 一种阿奇霉素药物原料及其制剂和用途
WO2015070131A1 (fr) * 2013-11-11 2015-05-14 Forest Laboratories Holdings Limited Compositions et méthodes de traitement à base de disodium de fosfomycine
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4382085A (en) * 1982-03-01 1983-05-03 Pfizer Inc. 4"-Epi erythromycin A and derivatives thereof as useful antibacterial agents
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RO107257B1 (ro) 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (fr) * 1987-09-10 1989-03-23 Pfizer Azithromycine et derives utilises comme agents anti-protozoaires
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
EP0553353A1 (fr) * 1990-10-15 1993-08-04 Taisho Pharmaceutical Co. Ltd Erythromycine modifiee en 2' ou derive de cette substance
TW271400B (fr) * 1992-07-30 1996-03-01 Pfizer
EP0721324A1 (fr) 1993-10-01 1996-07-17 The Procter & Gamble Company Utilisation de l'azithromycine pour le traitement de la parodontite de l'adulte
EP0758244B2 (fr) 1994-05-06 2008-02-13 Pfizer Inc. Formes galeniques a liberation controlee de l'azithromycine

Also Published As

Publication number Publication date
CN1114879A (zh) 1996-01-17
GR3031290T3 (en) 1999-12-31
JPH07300420A (ja) 1995-11-14
FI952060A7 (fi) 1995-10-30
AP9500728A0 (en) 1995-04-30
RU95106639A (ru) 1997-01-20
ZA953439B (en) 1996-10-28
IL113437A (en) 2001-04-30
HUT75244A (en) 1997-05-28
RU2128998C1 (ru) 1999-04-20
NO314386B1 (no) 2003-03-17
SI0679400T1 (en) 1999-10-31
YU49483B (sh) 2006-08-17
CN1088362C (zh) 2002-07-31
KR100354310B1 (ko) 2002-12-26
FI952060L (fi) 1995-10-30
TNSN95046A1 (fr) 1996-02-06
ES2136247T3 (es) 1999-11-16
LV10918A (lv) 1995-12-20
YU27195A (sh) 1999-03-04
ATE183395T1 (de) 1999-09-15
US5605889A (en) 1997-02-25
AU709328B2 (en) 1999-08-26
JP2008231120A (ja) 2008-10-02
IL113437A0 (en) 1995-07-31
UY23935A1 (es) 1995-09-12
UA34464C2 (uk) 2001-03-15
AU1771195A (en) 1995-11-09
DK0679400T3 (da) 1999-12-06
USRE39149E1 (en) 2006-06-27
CA2148071C (fr) 2000-10-17
AP566A (en) 1996-11-22
TW499311B (en) 2002-08-21
OA10151A (en) 1996-12-18
NO951630D0 (no) 1995-04-28
LV10918B (en) 1996-06-20
CA2148071A1 (fr) 1995-10-30
KR950028764A (ko) 1995-11-22
DE69511451T2 (de) 1999-12-09
DE69511451D1 (de) 1999-09-23
NZ548384A (en) 2008-04-30
EP0679400A1 (fr) 1995-11-02
NO951630L (no) 1995-10-30
HU9501206D0 (en) 1995-06-28
CO4560547A1 (es) 1998-02-10
MA23533A1 (fr) 1995-12-31
JP2005015466A (ja) 2005-01-20
EP0679400B1 (fr) 1999-08-18
FI952060A0 (fi) 1995-04-28

Similar Documents

Publication Publication Date Title
DZ1877A1 (fr) Forme posologiques d'azithromycine pour le traitement d'infection microbiennes.
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
MA25411A1 (fr) Microorganismes attenues pour le traitement d'infection.
EP0620256A3 (fr) Composition polymérique pour le traitement hydrophile.
OA09364A (fr) "Composition fongicide pour traitement de semences".
EP1390029A4 (fr) Phenylindoles pour le traitement de l'infection par le vih
MA25775A1 (fr) Combinaison des bacteries d'acide lactique et son utilisation pour la prevention et/ou le traitement des infections et des etats inflammatoires.
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
FR2689215B1 (fr) Installation de traitement d'air.
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
EP1037650A4 (fr) Procedes et compositions pour le traitement et la prevention d'infections a staphylococcus aureus
MA24339A1 (fr) Procede de preparation de medicaments destines au traitement d'infections bacteriennes en pediaterie
EP0689455A4 (fr) Strategies therapeutiques pour le traitement d'infections virales groupees immuno-infectieuses
MA26896A1 (fr) Utilisation de compositions d'antibiotiques azalides pour le traitement ou la prevention d'une infection par des bacteries ou protozoaires chez des mammiferes
FR2705966B1 (fr) Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
FR2746658B1 (fr) Valve de drainage implantable pour le traitement de l'hydrocephalie
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
FR2758465B1 (fr) Composition pour le traitement de l'amiante
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
MA25501A1 (fr) Traitement de l'endometriosis ou de la sterilite ou amelioration de la fertilite.
FI951655A7 (fi) H.pylori -infektioiden hoito
FR2658419B1 (fr) Medicament pour le traitement de la dermatite.
DZ2012A1 (fr) Benzamides pour le traitement de dégénérescences neurologiques.
EP0859761A4 (fr) 4-azasteroides utilises pour le traitement d'etats hyperandrogeniques